Contrasting Halozyme Therapeutics (HALO) and The Competition

Halozyme Therapeutics (NASDAQ: HALO) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Halozyme Therapeutics to related businesses based on the strength of its earnings, valuation, risk, dividends, profitability, institutional ownership and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Halozyme Therapeutics and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halozyme Therapeutics 1 2 4 0 2.43
Halozyme Therapeutics Competitors 1367 4435 12213 310 2.63

Halozyme Therapeutics presently has a consensus price target of $14.86, indicating a potential upside of 13.76%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 34.09%. Given Halozyme Therapeutics’ peers stronger consensus rating and higher probable upside, analysts clearly believe Halozyme Therapeutics has less favorable growth aspects than its peers.

Risk & Volatility

Halozyme Therapeutics has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics’ peers have a beta of 6.60, suggesting that their average stock price is 560% more volatile than the S&P 500.

Valuation & Earnings

This table compares Halozyme Therapeutics and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Halozyme Therapeutics $134.17 million -$95.85 million -14.04
Halozyme Therapeutics Competitors $464.68 million $167.59 million -6.46

Halozyme Therapeutics’ peers have higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Halozyme Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Halozyme Therapeutics -89.43% N/A -43.03%
Halozyme Therapeutics Competitors -4,734.60% -354.17% -43.01%

Insider and Institutional Ownership

85.1% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 51.8% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.8% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Halozyme Therapeutics peers beat Halozyme Therapeutics on 9 of the 12 factors compared.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant. The Company’s development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply